CrystalGenomics, Inc.

KOSDAQ 083790.KQ

CrystalGenomics, Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 39.46 M

CrystalGenomics, Inc. Cash and Short-Term Investments is USD 39.46 M for the year ending December 31, 2023, a -39.11% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

CrystalGenomics, Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 64.81 M, a -36.79% change year over year.
CrystalGenomics, Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 102.53 M, a -19.71% change year over year.
CrystalGenomics, Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 127.70 M, a 0.23% change year over year.
CrystalGenomics, Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 127.41 M, a -9.94% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 083790.KQ

CrystalGenomics, Inc.

CEO	Dr. Joong-Myung Cho Ph.D.
IPO Date	Jan. 6, 2006
Location	South Korea
Headquarters	Tower A, Korea Bio Park
Employees	65
Sector	Healthcare
Industries Biotechnology Clinical Trials Personal Care Pharmaceuticals Plastics Vaccines

Description

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years